Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140420 · ClinicalTrials.gov registry record · Phase 4
Naltrexone for Prolonged Grief Disorder
A Phase 4 study, sponsored by Texas Tech University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT06140420 is a Phase 4 study that was terminated before completion, run by Texas Tech University. The registered enrollment target is 7 participants.
The verdict
NCT06140420, a Phase 4 study, was terminated before completion, sponsored by Texas Tech University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Interventions
- DRUG Placebo
- DRUG Naltrexone Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06140420
The ClinicalTrials.gov registry entry for NCT06140420 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06140420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06140420 about?
NCT06140420 is a clinical study titled "Naltrexone for Prolonged Grief Disorder". This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
What is the current status of trial NCT06140420?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2023-08-01. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT06140420?
The interventions under investigation include: Placebo (DRUG), Naltrexone Oral Product (DRUG).
Who is sponsoring clinical trial NCT06140420?
This trial is sponsored by Texas Tech University, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.